FDA grants orphan drug status to Octant’s OCT-980 for RP
The regulatory status specifically includes RHO-adRP, the indication for which the candidate is presently being evaluated.
Drug Development
Arrowhead gains UK marketing authorisation for Redemplo
Regeneron agrees to $270m extension to supply Ebola medicine in US
China’s NMPA accepts Innovent application for sintilimab combo
Lunit and Summit to evaluate pathology platform for tumour analysis
Pathos AI completes $237m Series E round to expand oncology pipeline
Boehringer and Microsoft collaborate to explore AI in clinical research
Celltrion and Kaigene sign $580m licence deal for KG013
